Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (731-740 of 817) with videos related to

Pageof 82
Sort By:
Translational Lung Cancer Research|October 17, 2022
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patientsKohei Kushiro, Satoshi Watanabe, Yuka Goto, et al.
JTO Clinical and Research Reports|May 6, 2024
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060Takehiro Tozuka, Yuji Minegishi, Ou Yamaguchi, et al.
Ebiomedicine|November 7, 2017
Assessment of ATP8B1 Deficiency in Pediatric Patients With Cholestasis Using Peripheral Blood Monocyte-Derived MacrophagesHisamitsu Hayashi, Sotaro Naoi, Takao Togawa, et al.
Respiratory Medicine|February 1, 2017
Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE)Yoshiyuki Oyama, Noriyuki Enomoto, Yuzo Suzuki, et al.
Nature Communications|June 3, 2014
De novo SOX11 mutations cause Coffin-Siris syndromeYoshinori Tsurusaki, Eriko Koshimizu, Hirofumi Ohashi, et al.
Cancer Medicine|March 10, 2020
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapySatoshi Watanabe, Takeshi Ota, Masachika Hayashi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2015
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting ChemotherapyYu Saida, Satoshi Watanabe, Tomohiro Tanaka, et al.
Scientific Reports|April 17, 2022
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLCKenichi Koyama, Satoru Miura, Satoshi Watanabe, et al.
Thoracic Cancer|September 12, 2019
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastasesYu Saida, Satoshi Watanabe, Tetsuya Abe, et al.
International Journal of Molecular Sciences|August 9, 2020
The Sphingosine Kinase 1 Inhibitor, PF543, Mitigates Pulmonary Fibrosis by Reducing Lung Epithelial Cell mtDNA Damage and Recruitment of Fibrogenic MonocytesPaul Cheresh, Seok-Jo Kim, Long Shuang Huang, et al.
Pageof 82

Showing results (731-740 of 817) with videos related to

Sort By:
Pageof 82
Translational Lung Cancer Research|October 17, 2022
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patientsKohei Kushiro, Satoshi Watanabe, Yuka Goto, et al.
JTO Clinical and Research Reports|May 6, 2024
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060Takehiro Tozuka, Yuji Minegishi, Ou Yamaguchi, et al.
Ebiomedicine|November 7, 2017
Assessment of ATP8B1 Deficiency in Pediatric Patients With Cholestasis Using Peripheral Blood Monocyte-Derived MacrophagesHisamitsu Hayashi, Sotaro Naoi, Takao Togawa, et al.
Respiratory Medicine|February 1, 2017
Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE)Yoshiyuki Oyama, Noriyuki Enomoto, Yuzo Suzuki, et al.
Nature Communications|June 3, 2014
De novo SOX11 mutations cause Coffin-Siris syndromeYoshinori Tsurusaki, Eriko Koshimizu, Hirofumi Ohashi, et al.
Cancer Medicine|March 10, 2020
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapySatoshi Watanabe, Takeshi Ota, Masachika Hayashi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2015
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting ChemotherapyYu Saida, Satoshi Watanabe, Tomohiro Tanaka, et al.
Scientific Reports|April 17, 2022
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLCKenichi Koyama, Satoru Miura, Satoshi Watanabe, et al.
Thoracic Cancer|September 12, 2019
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastasesYu Saida, Satoshi Watanabe, Tetsuya Abe, et al.
International Journal of Molecular Sciences|August 9, 2020
The Sphingosine Kinase 1 Inhibitor, PF543, Mitigates Pulmonary Fibrosis by Reducing Lung Epithelial Cell mtDNA Damage and Recruitment of Fibrogenic MonocytesPaul Cheresh, Seok-Jo Kim, Long Shuang Huang, et al.
Pageof 82